NEW YORK, April 27, 2020 /PRNewswire/ -- Renalytix AI plc (LSE: RENX), the AIM-traded developer of clinical grade artificial intelligence in vitro diagnostics for kidney disease, announced today that it has received ISO 13485:2016 certification for its development and commercial laboratory
NEW YORK, April 27, 2020 /PRNewswire/ -- Renalytix AI plc (LSE: RENX), the AIM-traded developer of clinical grade artificial intelligence in vitro diagnostics for kidney disease, announced today that it has received ISO 13485:2016 certification for its development and commercial laboratory
Download full announcement Renalytix AI plc (LSE: RENX), the AIM-traded developer of clinical grade artificial intelligence in vitro diagnostics for kidney disease, announces that the KidneyIntelX ™ platform will be used by investigators from the Icahn School of Medicine at Mount Sinai to
NEW YORK, April 20, 2020 /PRNewswire/ -- Renalytix AI plc (LSE: RENX), the AIM-traded developer of clinical grade artificial intelligence in vitro diagnostics for kidney disease, announces that the KidneyIntelX™ platform will be used by investigators from the Icahn School of Medicine
Download full announcement Agreement with Three Rivers Provider Network, the fastest growing US proprietary provider network KidneyIntelX risk assessment testing now available to Three Rivers members and clients Renalytix AI plc (LSE: RENX), the AIM-traded developer of clinical grade artificial
Keyword Company EPIC/TIDM SEDOL/ISIN News Price Announcements Fundamentals News Article RSS Renalytix AI PLC (RENX) Add to Alerts list Print Mail a friend Wednesday 01 April, 2020 Renalytix AI PLC RNS Number : 3212I Renalytix AI PLC 01 April 2020 Renalytix AI plc
Renalytix AI plc (LSE: RENX), the AIM-traded developer of clinical grade artificial intelligence in vitro diagnostics for kidney disease, announces that further to RNS Reach 2937H on 24 March 2020, Boston Healthcare Associates has presented data on KidneyIntelX™, the Company’s AI-enabled in
Presentation titled: Evaluation of Payer Budget Impact Associated with the Use of Artificial Intelligence in vitro Diagnostic, KidneyIntelX™, to Modify DKD Progression Oral presentation accepted for Late Breaking session of the National Kidney Foundation Spring Clinical Meeting Accompanying
Oral presentation accepted for Late Breaking session of the National Kidney Foundation Spring Clinical Meeting Accompanying abstract accepted for publication in American Journal of Kidney Disease NEW YORK, March 24, 2020 /PRNewswire/ -- Renalytix AI plc (LSE: RENX), the AIM-traded developer of
